assays are unable to safely rule out myocardial infarction at presentation, Dr Kuan Ken Lee is a British Heart Foundation Clinical Research Fellow at the University of Edinburgh Centre for Cardiovascular Science and Specialty Trainee in Cardiology in the South East of Scotland. His research aims to improve our understanding of how high-sensitivity cardiac troponin can improve our risk stratification and selection of patients with acute chest pain for further investigation.
Professor Mills is the British Heart Foundation Butler Senior Clinical Research Fellow and a Professor of Cardiology at the University of Edinburgh. He is also a Consultant Interventional Cardiologist at the Royal Infirmary of Edinburgh working for the National Health Service in Scotland. His research aims to understand the mechanisms of myocardial injury in patients with heart disease, and to identify novel approaches to improve risk stratification and clinical outcomes in these patients. He is the chief investigator of a multi-centred cluster randomized trial evaluating the impact of a high sensitive troponin I assay on patients with suspected acute coronary syndrome (High-STEACS). Professor Mills has published more than 150 peer reviewed original articles and is a specialist member of the Diagnostics Advisory Committee for the National Institute of Health and Care Excellence (NICE) consultation on highsensitivity cardiac troponin. and therefore national and international guidelines have recommended admission to hospital for serial troponin testing for most patients. 3, 4 Recent technological advances have led to the development of highly sensitive assays with the ability to quantify 10-to 100-fold lower concentrations of cardiac troponin with greater precision than previous generations of contemporary assays. 5 This enhanced analytical performance at very low concentrations now permits us to detect troponin in the majority of healthy persons and to use this information to guide clinical decisions. We previously defined a threshold below the 99th centile upper reference limit used to diagnose myocardial infarction that identifies patients at presentation who are low risk and may be suitable for immediate discharge. 6 In a prospective study of 6304 patients, more than half had high-sensitivity cardiac troponin concentrations of <5 ng/L and this threshold had a negative predictive value (NPV) of 99.6% for myocardial infarction or cardiac death at 30 days. 6 We subsequently performed a systematic review and individual patient-level data meta-analysis to determine the generalizability of this threshold across different patient populations and healthcare systems. 7 Following a systematic search of the literature, we identified 19 prospective cohort studies across 9 different countries of patients investigated for suspected acute coronary syndrome using the same high-sensitive cardiac troponin I assay at presentation. All corresponding authors from the cohorts identified in the systematic review agreed to participate, allowing us to pool data from 22 457 patients. . This approach to risk stratification using low levels of cardiac troponin has potential to improve efficiency in the delivery of health care and is currently being formally evaluated in a prospective multicentre clinical trial (NCT03005158). Furthermore, high-sensitivity cardiac troponin concentrations well below the threshold used to diagnose myocardial infarction may improve our ability to identify patients with stable coronary artery disease. Patients with angina pectoris and high-risk coronary plaque detected by 18 F-Sodium Fluoride PET-CT imaging have higher troponin concentrations than those without evidence of active plaque disease. 8 In a sub-study of the SCOT-HEART trial, cardiac troponin was measured using a high-sensitivity single-molecule counting assay in 943 patients with suspected stable angina who had undergone computed tomography coronary angiography. 9 Cardiac troponin concentrations were associated with presence of obstructive coronary artery disease with a 5-fold increase across quintiles (9% to 48%; P < 0.001) and this association was independent of known cardiovascular risk factors (odds ratio, 1.35 [95%CI of 1.25-1.46] per doubling of troponin). In our prospective cohort study, one in three patients without myocardial infarction have high-sensitivity cardiac troponin between 5 ng/L and the 99th centile diagnostic threshold, and this group of patients were 10 times more likely to have a major cardiac event at 1 year compared to those with concentration <5 ng/L. 7 Randomized controlled trials are urgently needed to investigate whether risk stratification of patients without myocardial infarction using high-sensitivity cardiac troponin will lead to more efficient use of resources and better patient outcomes through improved targeting of investigations and treatments for coronary heart disease in those at intermediate risk.
The high-sensitivity cardiac troponin I assay used in many of our studies is a chemiluminescent microparticle immunoassay designed to quantify cardiac troponin in plasma and serum. It has a limit of detection of 1.2 ng/L and able to measure cardiac troponin in 96% of presumed healthy individuals with an inter-assay coefficient of variation <10% at 4.7 ng/L. 5 However, there is significant heterogeneity between different high-sensitivity cardiac troponin assays. 5 Whilst analytical performance may be sufficient to rule in and rule out acute myocardial infarction, there is concern regarding imprecision at lower levels in patients with stable coronary and cardiovascular disease. More recently, novel approaches to protein measurement have been developed with the ability to quantify at the single-molecule level. 10 One such commercially available assay involves the formation of immunosandwich complexes using biotinylated capture reagent and highly specific fluorescent-labelled detectors on solid plates that are passed through a laser for singlemolecule counting. 10 Immunoassay technology with exceptional precision at very low concentrations has great potential for precision medicine approaches to improve the targeting of therapies in the prevention of heart disease.
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Even though cardiac troponin is an excellent prognostic marker, it is not in isolation able to define the underlying aetiology of myocardial injury, which may occur in many conditions other than coronary artery disease, such as in hypertensive or valvular heart disease, chronic kidney disease, and even after intense exercise. 12, 13 As such, the interpretation of cardiac troponin concentrations can be challenging in various clinical scenarios. Many aspects of the cellular release of cardiac troponin and its degradation are still incompletely understood. 14 It is likely that different mechanisms of release occur in different pathophysiological conditions, where injury may occur due to mechanical shear stress or direct cytotoxicity, rather than from transient or persistent myocardial ischemia and necrosis. Distinct pathological processes may also result in different patterns of sarcomeric protein release. Further basic science research to elucidate the mechanisms of troponin and other sarcomeric protein release may help to develop new strategies that discriminate between the different underlying aetiologies of myocardial injury. Recently, cardiac myosin-binding protein C (cMyC) has been evaluated as a promising new biomarker for the diagnosis of myocardial infarction. 15 Whether combining troponin testing with other biomarkers, such as cMyC, will improve our ability to identify patients with myocardial injury due to coronary artery disease will require further investigation. As the role of cardiac troponin as a barometer for cardiac health in patients without myocardial infarction becomes more established, access to cardiac troponin assays with excellent analytical precision at low concentrations will be essential in both primary and secondary care.
This should encourage scientists to develop close collaboration with clinicians to translate advances in assay technology into novel clinical applications.
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